You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Article metrics

Article menu
XML
Emerging technologies, pharmacology and therapeutics
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

 

Online download statistics by month:

Online download statistics by month: May 2021 to March 2024

AbstractFullPdf
May 2021806781343
Jun 2021370345127
Jul 2021257244106
Aug 2021342309109
Sep 202135232674
Oct 202140239782
Nov 202126623863
Dec 202137335082
Jan 202249548392
Feb 2022375369162
Mar 2022475459141
Apr 2022578585115
May 2022422443109
Jun 202233433295
Jul 2022296276131
Aug 202221119671
Sep 202223420961
Oct 2022314298101
Nov 202229827674
Dec 202223522562
Jan 202325724875
Feb 202325424875
Mar 202322121869
Apr 202320119365
May 202325323373
Jul 202323723288
Aug 202322621665
Sep 202326024768
Oct 202322321083
Nov 202328026463
Dec 202316813630
Jan 202415210841
Feb 202420616966
Mar 2024257229117
Total10630100923178